Onkure Therapeutics, INC 10-Q quarterly reports

OnKure Therapeutics, Inc. filed its Form 10-Q for the period ending June 30, 2026, detailing financial performance, ongoing R&D, and a significant private placement.

OnKure Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting a significant increase in cash and cash equivalents following a private placement, while continuing to advance its pipeline of precision medicines.

OnKure Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses and a significant decrease in cash and cash equivalents for the third quarter of 2025, highlighting ongoing funding needs for its cancer drug development.

OnKure Therapeutics reported a widened net loss in Q2 2025, driven by increased research and development expenses for its lead cancer drug candidate, OKI-219, while maintaining sufficient cash runway for the next 12 months.

OnKure Therapeutics reports its first financial results post-merger, highlighting ongoing clinical trials and a focus on precision medicines for cancer.

OnKure Therapeutics, formerly Reneo Pharmaceuticals, completed its merger and reported its financial results for the quarter ended September 30, 2024.

Reneo Pharmaceuticals has entered into a merger agreement with OnKure, Inc., while also suspending development of its lead drug candidate, mavodelpar, following disappointing trial results.

Reneo Pharmaceuticals reports a net loss of $8.4 million for the first quarter of 2024, as it continues to evaluate strategic alternatives following the suspension of its lead drug development program.